Cargando…

Hepatic steatosis in women with polycystic ovary syndrome

BACKGROUND: This multi-center, cross-sectional study intended to explore the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with polycystic ovary syndrome (PCOS). METHODS: Patients who met the PCOS...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Xinyu, Guo, Zaixin, Yu, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521461/
https://www.ncbi.nlm.nih.gov/pubmed/37752440
http://dx.doi.org/10.1186/s12902-023-01456-6
_version_ 1785110131686506496
author Hong, Xinyu
Guo, Zaixin
Yu, Qi
author_facet Hong, Xinyu
Guo, Zaixin
Yu, Qi
author_sort Hong, Xinyu
collection PubMed
description BACKGROUND: This multi-center, cross-sectional study intended to explore the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with polycystic ovary syndrome (PCOS). METHODS: Patients who met the PCOS Rotterdam diagnostic criteria were enrolled in 6 centers in China, and age-matched healthy volunteers were also recruited. Data were collected including medical history, physical characteristics, and blood tests (liver function, blood lipids, blood glucose and insulin, sex hormones, etc.). Transvaginal or transrectal ultrasound was employed to identify polycystic ovarian morphology (PCOM). The serological score Liver Fat Score (LFS) >-0.640 was used for the diagnosis of NAFLD, and the diagnosis of MAFLD was made according to the 2020 new definition. RESULTS: A total of 217 PCOS patients and 72 healthy controls were included. PCOS patients had impaired glucose and lipid metabolism, higher liver enzymes and LFS. Both NAFLD (33.6%) and MAFLD (42.8%) was more prevalent in PCOS patients than in controls (4.2%, P < 0.001). Logistic regression results showed that HOMA-IR ≥ 3.54 and ALT ≥ 18.2 were independently associated with NAFLD (P < 0.001) and MAFLD (P ≤ 0.001). The prevalence of NAFLD was significantly higher in PCOS patients with free androgen index (FAI) > 8 (53.8% versus 17.4%, P < 0.001) and BMI ≥ 24 kg/m(2) (57.3%, 11.3%, P < 0.001). CONCLUSION: The prevalence of NAFLD/MAFLD in PCOS patients was significantly higher than that in healthy controls and was independently associated with HOMA-IR and ALT. PCOS patients with overweight and elevated FAI have a higher prevalence of fatty liver. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12902-023-01456-6.
format Online
Article
Text
id pubmed-10521461
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105214612023-09-27 Hepatic steatosis in women with polycystic ovary syndrome Hong, Xinyu Guo, Zaixin Yu, Qi BMC Endocr Disord Research BACKGROUND: This multi-center, cross-sectional study intended to explore the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with polycystic ovary syndrome (PCOS). METHODS: Patients who met the PCOS Rotterdam diagnostic criteria were enrolled in 6 centers in China, and age-matched healthy volunteers were also recruited. Data were collected including medical history, physical characteristics, and blood tests (liver function, blood lipids, blood glucose and insulin, sex hormones, etc.). Transvaginal or transrectal ultrasound was employed to identify polycystic ovarian morphology (PCOM). The serological score Liver Fat Score (LFS) >-0.640 was used for the diagnosis of NAFLD, and the diagnosis of MAFLD was made according to the 2020 new definition. RESULTS: A total of 217 PCOS patients and 72 healthy controls were included. PCOS patients had impaired glucose and lipid metabolism, higher liver enzymes and LFS. Both NAFLD (33.6%) and MAFLD (42.8%) was more prevalent in PCOS patients than in controls (4.2%, P < 0.001). Logistic regression results showed that HOMA-IR ≥ 3.54 and ALT ≥ 18.2 were independently associated with NAFLD (P < 0.001) and MAFLD (P ≤ 0.001). The prevalence of NAFLD was significantly higher in PCOS patients with free androgen index (FAI) > 8 (53.8% versus 17.4%, P < 0.001) and BMI ≥ 24 kg/m(2) (57.3%, 11.3%, P < 0.001). CONCLUSION: The prevalence of NAFLD/MAFLD in PCOS patients was significantly higher than that in healthy controls and was independently associated with HOMA-IR and ALT. PCOS patients with overweight and elevated FAI have a higher prevalence of fatty liver. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12902-023-01456-6. BioMed Central 2023-09-26 /pmc/articles/PMC10521461/ /pubmed/37752440 http://dx.doi.org/10.1186/s12902-023-01456-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hong, Xinyu
Guo, Zaixin
Yu, Qi
Hepatic steatosis in women with polycystic ovary syndrome
title Hepatic steatosis in women with polycystic ovary syndrome
title_full Hepatic steatosis in women with polycystic ovary syndrome
title_fullStr Hepatic steatosis in women with polycystic ovary syndrome
title_full_unstemmed Hepatic steatosis in women with polycystic ovary syndrome
title_short Hepatic steatosis in women with polycystic ovary syndrome
title_sort hepatic steatosis in women with polycystic ovary syndrome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521461/
https://www.ncbi.nlm.nih.gov/pubmed/37752440
http://dx.doi.org/10.1186/s12902-023-01456-6
work_keys_str_mv AT hongxinyu hepaticsteatosisinwomenwithpolycysticovarysyndrome
AT guozaixin hepaticsteatosisinwomenwithpolycysticovarysyndrome
AT yuqi hepaticsteatosisinwomenwithpolycysticovarysyndrome